Sanofi presents detailed asthma trial data while AstraZeneca reports positive COPD results at ERS 2026

At the European Respiratory Society meeting in Barcelona, Sanofi disclosed detailed findings from its asthma trial, building on earlier indications of efficacy.

The data highlighted specific endpoints such as improvement in lung function and symptom control, with results aligning with the company's prior expectations.

AstraZeneca also shared outcomes from its COPD study, reporting statistically significant benefits in patient-reported outcomes and lung capacity measures.

Both companies framed the results as confirming the therapeutic potential of their respective programs, suggesting continued development and possible future regulatory submissions.